
The FDA's psychedelic sea-change: what accelerated clinical trials for psilocybin, methylone, and ibogaine mean for mental health and neuroscience research | Boris Heifets
Episode 8
Last month we saw a big shift in the federal government’s approach to psychedelic medicine. Specifically, following an executive order by President Trump, the FDA announced it is fast-tracking its review of several clinical trials of psychedelic drugs for patients with mental health disorders. The executive order also directed more funds towards psychedelic research and a review of psychedelics’ status as highly restricted Schedule 1 substances. To help us understand what all this means for the future of psychedelic medicine and the neuroscience of psychedelics, we’re joined by Boris Heifets, an anesthesiologist at Stanford Medicine who runs a lab studying how psychedelics affect the nervous system and their impact on patients with psychiatric conditions. Learn More The Heifets Lab at Stanford Medicine FDA plans ultra-fast review of three psychedelic drugs following Trump directive (Associated Press, 2026) Trump’s order on psychedelics could have far-reaching science consequences (Scientific American, 2026) Psychedelics, placebo, and anesthetic dreams (From Our Neurons to Yours, 2024) Pychedelics inside out — how do LSD and psilocybin alter perception?
Publisher
From Our Neurons to Yours
Published
May 7, 2026
Duration
46 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
Wu Tsai Neurosciences Institute at Stanford University, Nicholas Weiler
From Our Neurons to Yours
@fromourneuronstoyours
#fdaspsychedelicsea #acceleratedclinicaltrials #neuroscienceresearch #lifesciences #mentalhealth
